James E. Fickenscher
2022 - Zynerba Pharmaceuticals
In 2022, James E. Fickenscher earned a total compensation of $1.3M as CFO and VP, Corporate Development at Zynerba Pharmaceuticals, a 5% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $141,187 |
---|---|
Option Awards | $242,413 |
Salary | $449,253 |
Stock Awards | $409,700 |
Other | $17,182 |
Total | $1,259,735 |
Fickenscher received $449.3K in salary, accounting for 36% of the total pay in 2022.
Fickenscher also received $141.2K in non-equity incentive plan, $242.4K in option awards, $409.7K in stock awards and $17.2K in other compensation.
Rankings
In 2022, James E. Fickenscher's compensation ranked 2,587th out of 5,753 executives tracked by ExecPay. In other words, Fickenscher earned more than 55.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,587 | 55th |
Manufacturing | 1,435 | 54th |
Chemicals And Allied Products | 652 | 54th |
Drugs | 606 | 54th |
Pharmaceutical Preparations | 435 | 55th |
Fickenscher's colleagues
We found two more compensation records of executives who worked with James E. Fickenscher at Zynerba Pharmaceuticals in 2022.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019